TheraCryf (FRA:8EV) Other Net Income (Loss) : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Other Net Income (Loss)?

TheraCryf's Other Net Income (Loss) for the six months ended in Sep. 2023 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

TheraCryf's quarterly Other Net Income (Loss) increased from Sep. 2022 (€0.00 Mil) to Mar. 2023 (€0.00 Mil) but then declined from Mar. 2023 (€0.00 Mil) to Sep. 2023 (€0.00 Mil).

TheraCryf's annual Other Net Income (Loss) increased from Mar. 2021 (€-0.00 Mil) to Mar. 2022 (€0.00 Mil) but then declined from Mar. 2022 (€0.00 Mil) to Mar. 2023 (€-0.00 Mil).

TheraCryf Other Net Income (Loss) Historical Data

The historical data trend for TheraCryf's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Other Net Income (Loss) Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Other Net Income (Loss)

Get a 7-Day Free Trial

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

TheraCryf Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

TheraCryf Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of TheraCryf's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (FRA:8EV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

EVG:UK

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines